CELLECT BIOTECH / S (APOP) Gaining a somewhat positive news coverage, shows a study

The news from CELLECT BIOTECH / S (NASDAQ: APOP) is rather positive on Tuesday, according to Accern. the feeling of media coverage by reviewing in real time more than 20 million sources of blogs and news.Accern ranks the coverage of public companies on a scale from negative to positive, the scores closest to one being the most favorable. Accern also attributed to the press an impact rating of 45.654222275834 out of 100, indicating that recent media coverage is unlikely to have any impact on the company's share price in a near future. 19659002] The shares of CELLECT BIOTECH / S fell by $ 0.17, reaching $ 7.16 during trading hours on Tuesday, reports Marketbeat.com, 13,400 shares of the company traded for 58,612 shares. IOTECH / S has a minimum of $ 6.12 over 12 months and a high of $ 12.50 over 12 months. The company has a market capitalization of $ 39.52 million, a price / earnings ratio of -4.90 and a beta of 4.69.

CELLECT BIOTECH / S (NASDAQ: APOP) last announced its quarterly results on Thursday, May 17th. The company reported ($ 0.16) earnings per share for the quarter, exceeding the consensus estimate by Thomson Reuters by $ 0.14 ($ 0.30). Analysts expect CELLECT BIOTECH / S to post -1 earnings per share for the current year.

Several stock badysts have recently published reports on APOP shares. HC Wainwright reiterated a "buy" note and set a target price of $ 14.00 on CELLECT BIOTECH / S shares in a report on Tuesday, May 29. Zacks Investment Research upgraded CELLECT BIOTECH / S shares from a "hold" rating to a "buy" rating and set a target price of $ 7.25 for the company in a report on Friday April 6th. Finally, ValuEngine has updated the shares of CELLECT BIOTECH / S from a "sell" rating to a "hold" note in a report released on Wednesday, June 6th.

About CELLECT BIOTECH / S

Cellect Biotechnology Ltd, a biotechnology company, focuses on the development of technologies for the functional selection of stem cells in the field of regenerative medicine and cell-based therapies strains in Israel. Develops the Apotainer Selection Kit, a stem cell selection kit, based on its Powered by Cellect technology platform for allogeneic hematopoietic stem cell transplantation procedures in patients with hematologic malignancies

Receive news and updates from CELLECT BIOTECH / S Daily – Enter your email address below to receive a concise daily summary of news and badyst ratings for CELLECT BIOTECH / S and related companies with MarketBeat.com's free daily newsletter.